> ## Documentation Index
> Fetch the complete documentation index at: https://financecontext.com/llms.txt
> Use this file to discover all available pages before exploring further.

# buyer-list

> Build and organize a tiered universe of potential acquirers for sell-side M&A processes -- strategic buyers and financial sponsors

## What is a Buyer Universe?

A **buyer universe** is a comprehensive, researched, and prioritized list of every entity that might be interested in acquiring a company being sold. It is one of the first deliverables an investment bank produces when engaged on a sell-side M\&A mandate, because the buyer list determines who receives the teaser and CIM -- and ultimately who competes to buy the company.

Buyer universes include two fundamental categories. **Strategic buyers** are operating companies that would acquire the target for business reasons: gaining market share, expanding into new geographies, acquiring technology, or vertically integrating their supply chain. **Financial buyers** (also called financial sponsors) are private equity firms that acquire companies as investments, typically using leverage (debt) to amplify returns, with the goal of growing the business and selling it 3-7 years later.

The quality of the buyer list directly impacts deal outcomes. A well-researched list that identifies the "right" 30-40 buyers generates competitive tension, drives valuation higher, and produces a successful transaction. A lazy list of 200 names wastes time, risks information leaks, and signals desperation.

## Why It Matters

* **Competitive tension drives value**: More genuinely interested buyers means more competition, which drives higher bids. The ideal outcome is 3-5 serious bidders in the final round
* **Process efficiency**: A focused, tiered list lets the bank prioritize outreach. Tier 1 buyers are contacted first; Tier 2 and 3 provide fallback options
* **Strategic fit assessment**: Not all buyers are equal. Understanding each buyer's strategic rationale, financial capacity, and M\&A track record lets the bank predict who will bid highest
* **Antitrust screening**: Some strategic buyers may face regulatory challenges. Identifying this early prevents wasted effort
* **Seller input**: The client often has preferences (or exclusions) about who should or should not be approached. The buyer list is where these are documented

## Key Concepts

| Term                    | Definition                                                                                                     |
| ----------------------- | -------------------------------------------------------------------------------------------------------------- |
| **Strategic Buyer**     | An operating company acquiring for business synergies (revenue growth, cost savings, market share)             |
| **Financial Sponsor**   | A private equity firm acquiring as an investment, typically using leverage                                     |
| **Platform Investment** | When a PE firm acquires a company as the foundation for building a larger business through add-on acquisitions |
| **Add-on / Bolt-on**    | A smaller acquisition by a PE portfolio company to expand capabilities, geography, or product lines            |
| **Tier 1 / 2 / 3**      | Priority ranking based on strategic fit, likelihood to bid, and financial capacity                             |
| **Contact Mapping**     | Identifying the right person to call at each buyer (CEO, Corp Dev head, PE Partner)                            |
| **M\&A Track Record**   | A buyer's history of acquisitions, indicating both capability and appetite                                     |

## Worked Example: Buyer Universe for Project Atlas (Specialty Chemicals)

Walk through building the complete buyer list for the Atlas Specialty Chemicals sell-side process.

### Step 1: Target Company Profile

| Attribute          | Detail                                                                         |
| ------------------ | ------------------------------------------------------------------------------ |
| Company            | Atlas Specialty Chemicals                                                      |
| Sector             | Specialty chemicals -- aerospace coatings                                      |
| Revenue            | \$85M                                                                          |
| EBITDA             | \$18M (21% margin)                                                             |
| Growth             | 12% CAGR                                                                       |
| Geography          | US-based, opening EMEA facility                                                |
| Key assets         | Aerospace qualifications, 175 customer relationships, proprietary formulations |
| Expected valuation | $180M-$216M (10-12x EBITDA)                                                    |
| Seller preference  | Open to both strategic and financial buyers; management willing to roll equity |

### Step 2: Strategic Buyer Identification

**Category 1: Direct Competitors (Specialty Coatings)**

| Buyer            | Revenue | Strategic Fit                                                  | Financial Capacity            | M\&A Track Record          | Likelihood | Tier  |
| ---------------- | ------- | -------------------------------------------------------------- | ----------------------------- | -------------------------- | ---------- | ----- |
| PPG Industries   | \$18.2B | HIGH -- Aerospace coatings division directly competitive       | HIGH -- \$5B+ cash + capacity | Active -- 3 deals in 2023  | HIGH       | **1** |
| Akzo Nobel       | \$11.5B | HIGH -- Aerospace segment, complementary geography (EU strong) | HIGH -- Investment grade      | Moderate -- 1 deal/year    | HIGH       | **1** |
| Sherwin-Williams | \$23.1B | MEDIUM -- General coatings, limited aerospace presence         | HIGH -- FCF machine           | Active -- 2-3 deals/year   | MEDIUM     | **2** |
| Hempel A/S       | \$2.5B  | MEDIUM -- Protective coatings, wants aerospace entry           | MEDIUM -- Private, Danish     | Low -- infrequent acquirer | LOW        | **3** |

**Category 2: Adjacent Players (Specialty Chemicals, Non-Coatings)**

| Buyer           | Revenue | Strategic Fit | Rationale                                     | Tier  |
| --------------- | ------- | ------------- | --------------------------------------------- | ----- |
| Hexion          | \$3.8B  | MEDIUM        | Specialty resins; coatings expansion strategy | **2** |
| Cabot Corp      | \$4.1B  | MEDIUM        | Specialty chemicals; aerospace materials      | **2** |
| Quaker Houghton | \$1.9B  | MEDIUM        | Specialty fluids; aerospace exposure          | **2** |
| Evonik          | \$17.5B | LOW           | Diversified specialty chemicals               | **3** |

**Category 3: Vertical Integrators (Aerospace Supply Chain)**

| Buyer          | Revenue | Strategic Fit | Rationale                                                  | Tier  |
| -------------- | ------- | ------------- | ---------------------------------------------------------- | ----- |
| Henkel         | \$22.5B | MEDIUM        | Adhesives/coatings; aerospace OEM relationships            | **2** |
| 3M             | \$32.7B | LOW           | Diversified; aerospace segment but strategic focus unclear | **3** |
| Cytec (Solvay) | \$12.9B | MEDIUM        | Advanced materials for aerospace                           | **2** |

**Category 4: Platform Builders (Large Industrials Doing M\&A in Specialty Chemicals)**

| Buyer              | Revenue | Strategic Fit | Rationale                                              | Tier  |
| ------------------ | ------- | ------------- | ------------------------------------------------------ | ----- |
| IDEX Corp          | \$3.3B  | MEDIUM        | Specialty industrial acquirer; disciplined M\&A        | **2** |
| Roper Technologies | \$5.8B  | LOW           | Niche industrial, but typically asset-light businesses | **3** |

### Step 3: Financial Sponsor Identification

**Platform Investors (No Existing Portfolio Company in Sector)**

| Sponsor                     | Fund Size | Sector Focus              | Deal Size Range | Recent Activity               | Tier  |
| --------------------------- | --------- | ------------------------- | --------------- | ----------------------------- | ----- |
| Arsenal Capital             | \$5.0B    | Specialty chemicals focus | \$100-500M EV   | Platform: ChemTreat (2021)    | **1** |
| American Securities         | \$8.0B    | Industrials/chemicals     | \$200M-2B EV    | Active in specialty chemicals | **1** |
| Audax Private Equity        | \$3.5B    | Mid-market industrials    | \$50-300M EV    | Sector thesis in chemicals    | **2** |
| Odyssey Investment Partners | \$2.5B    | Industrial/manufacturing  | \$100-500M EV   | 2 chemical platforms          | **2** |

**Add-on Buyers (PE Firms with Existing Chemical Platforms)**

| Sponsor        | Portfolio Company                 | Portfolio Revenue | Add-on Fit                                | Tier  |
| -------------- | --------------------------------- | ----------------- | ----------------------------------------- | ----- |
| Carlyle Group  | Nouryon (specialty chemicals)     | \$5.5B            | HIGH -- coatings adjacency                | **1** |
| Bain Capital   | Diversey (specialty chemicals)    | \$2.8B            | MEDIUM -- different end market            | **2** |
| Warburg Pincus | ChemPoint (chemical distribution) | \$800M            | MEDIUM -- distribution, not manufacturing | **3** |
| HGGC           | SpecChem Holdings (hypothetical)  | \$120M            | HIGH -- direct bolt-on                    | **1** |

**Growth Equity (Not Applicable)**
Atlas is a mature, profitable business. Growth equity firms typically invest in earlier-stage, high-growth companies. This category is not relevant for this transaction.

### Step 4: Prioritization Summary

| Tier       | Count         | Who                                                                                         | Outreach Strategy                                                                |
| ---------- | ------------- | ------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------- |
| **Tier 1** | 7 buyers      | PPG, Akzo Nobel, Arsenal, American Securities, Carlyle/Nouryon, HGGC/SpecChem, one add-on   | Contact first wave. Senior banker calls Corp Dev head or PE Partner directly.    |
| **Tier 2** | 10 buyers     | Sherwin-Williams, Hexion, Cabot, Quaker Houghton, Henkel, Cytec, IDEX, Audax, Odyssey, Bain | Contact second wave (1 week after Tier 1). Mix of calls and teaser distribution. |
| **Tier 3** | 6 buyers      | Hempel, Evonik, 3M, Roper, Warburg, other                                                   | Contact only if Tier 1-2 response rate is low. Teaser distribution.              |
| **Total**  | **23 buyers** |                                                                                             |                                                                                  |

### Step 5: Contact Mapping (Tier 1)

| Buyer               | Key Contact    | Title             | Relationship                          | Approach                            |
| ------------------- | -------------- | ----------------- | ------------------------------------- | ----------------------------------- |
| PPG Industries      | Sarah Chen     | VP Corp Dev       | Existing -- met at JPM conference     | MD phone call, then teaser          |
| Akzo Nobel          | Jan de Vries   | Head M\&A EMEA    | Cold -- no prior relationship         | Email introduction via network      |
| Arsenal Capital     | Michael Torres | Partner           | Strong -- closed 2 deals together     | MD phone call directly              |
| American Securities | David Kim      | Managing Director | Moderate -- met at ACG conference     | VP introductory call                |
| Carlyle (Nouryon)   | James Wright   | Operating Partner | Existing -- co-investor on prior deal | MD phone call                       |
| HGGC (SpecChem)     | Lisa Patel     | Partner           | Cold                                  | Warm introduction via legal counsel |
| (7th buyer)         | TBD            | TBD               | TBD                                   | TBD                                 |

## Full Skill Workflow (From SKILL.md)

### Phase 1: Understand the Target

Gather target company details before identifying buyers:

* Company description, sector, and business model
* Revenue, EBITDA, and growth profile
* Key assets and capabilities (IP, customer relationships, geographic footprint, team)
* Expected valuation range
* Seller preferences (strategic vs. financial, management continuity, timeline)
* **Exclusion list**: Companies the seller does not want contacted (competitors they do not trust with confidential information, companies with difficult relationships)

### Phase 2: Identify Strategic Buyers

Research across four categories:

**Direct Competitors:** Companies in the same space that would gain market share. Rationale: revenue synergies, eliminate competitor, scale economies.

**Adjacent Players:** Companies in adjacent markets that could expand into the target's space. Rationale: product extension, cross-sell, new market entry.

**Vertical Integrators:** Customers or suppliers that could integrate vertically. Rationale: supply chain control, margin capture, strategic lock-in.

**Platform Builders:** Large companies building a platform in the space through M\&A. Rationale: tuck-in acquisition, fill capability gap.

For each strategic buyer, assess:

* **Strategic fit**: How well does the target complement the buyer's existing business?
* **Financial capacity**: Can they afford the expected price? (Check market cap, cash, debt capacity)
* **M\&A track record**: Have they completed acquisitions recently? Are they active or dormant?
* **Antitrust risk**: Would the combination face regulatory scrutiny?

### Phase 3: Identify Financial Sponsors

Research across three types:

**Platform Investors:** PE firms looking for a new platform in this sector. Check: fund size (target deal should be 5-15% of fund), sector thesis, recent platform acquisitions in related spaces.

**Add-on Buyers:** PE firms with existing portfolio companies that could bolt on the target. This is often the most actionable category -- the portfolio company provides the strategic rationale, and the PE firm provides the capital.

**Growth Equity:** For earlier-stage or high-growth targets. Usually minority or majority preferred equity. Not applicable for mature, profitable businesses.

For each sponsor, assess:

* **Fund size and vintage**: A \$3B fund in year 3 has capital to deploy. The same fund in year 8 is harvesting, not deploying.
* **Sector focus**: Does the firm have a stated thesis in this sector?
* **Portfolio overlap**: Do they already own a company that would benefit from this acquisition?
* **Deal size range**: Does the expected valuation fit their typical check size?

### Phase 4: Prioritize and Tier

| Tier       | Criteria                                                                     | Count | Action                                        |
| ---------- | ---------------------------------------------------------------------------- | ----- | --------------------------------------------- |
| **Tier 1** | Highest strategic fit, proven acquirers, clear rationale, financial capacity | 5-10  | Contact first. Senior banker direct outreach. |
| **Tier 2** | Good fit but less obvious connection, or less active acquirers               | 10-15 | Contact second wave (1 week later).           |
| **Tier 3** | Possible but lower probability; backup options                               | 10-20 | Contact only if process needs broadening.     |

### Phase 5: Contact Mapping (Tier 1)

For each Tier 1 buyer, identify:

* Key decision maker (CEO, Corp Dev head, PE Partner)
* Relationship status (existing relationship, cold outreach, need introduction)
* Known preferences or constraints (size, geography, structure)
* Best approach channel (phone, email, in-person at conference)

### Phase 6: Deliver Output

* Excel workbook with strategic buyers tab (sorted by tier), financial sponsors tab (sorted by tier), contact mapping for Tier 1, and summary statistics
* One-page buyer universe summary for the engagement letter or pitch

## Common Mistakes (and How to Avoid Them)

<Accordion title="Mistake 1: Quantity Over Quality">
  **What goes wrong:** The buyer list has 200 names. The team sends teasers to all 200. Response rate is 5% (10 responses). Of those 10, only 3 are serious. The process wasted time on 197 unproductive contacts and created an impression of desperation.

  **How to avoid it:** Focus on 25-40 well-researched buyers. For each, document the specific strategic rationale. A buyer on the list without a clear rationale should not be on the list.
</Accordion>

<Accordion title="Mistake 2: Missing the Add-on Opportunity">
  **What goes wrong:** The buyer list includes 10 platform PE firms but zero add-on opportunities. In reality, the best buyer is a PE-backed portfolio company that would gain significant synergies from the acquisition. This buyer is never contacted.

  **How to avoid it:** Always research PE portfolio companies in the target's sector. Search PitchBook, Preqin, or the PE firms' websites for portfolio companies with complementary businesses. Add-on acquisitions often produce the highest bids because the portfolio company sees direct synergies.
</Accordion>

<Accordion title="Mistake 3: Not Checking Antitrust Risk">
  **What goes wrong:** The top strategic buyer submits the highest IOI. The process advances to final bids. During confirmatory diligence, antitrust counsel identifies a 70% probability of a second request from the FTC. The deal takes 18 months to close (if it closes at all). The seller could have avoided this by identifying the risk early.

  **How to avoid it:** For direct competitors with significant market share overlap, flag potential antitrust risk at the buyer list stage. This does not mean excluding them -- it means accounting for the risk in the evaluation criteria and having alternative buyers ready.
</Accordion>

<Accordion title="Mistake 4: Ignoring Fund Vintage for PE Buyers">
  **What goes wrong:** A PE firm is on the Tier 1 list because they have a strong sector thesis. But their latest fund is in year 7 with 90% deployed. They are in harvest mode, not deployment mode. They decline to participate.

  **How to avoid it:** Check fund vintage and deployment pace for every PE buyer. A fund in years 1-4 with less than 50% deployed is in the sweet spot for new platform investments. A fund in years 6-8 may only pursue add-ons for existing platforms.
</Accordion>

<Accordion title="Mistake 5: Not Asking the Seller About Preferences">
  **What goes wrong:** The bank contacts a direct competitor that the seller explicitly did not want to engage. The seller is furious -- they have a difficult relationship with that company, and sharing confidential information with them is unacceptable.

  **How to avoid it:** Before finalizing the buyer list, review it with the seller. Ask: "Are there any names you want included or excluded?" Document exclusions and the reasons. Some sellers will have strong feelings about specific companies.
</Accordion>

<Accordion title="Mistake 6: Static Buyer List">
  **What goes wrong:** The buyer list is finalized at the start of the process and never updated. A major M\&A deal changes the competitive landscape (a potential buyer acquires a competitor, changing their appetite). The list does not reflect the new reality.

  **How to avoid it:** The buyer list is a living document. Update it as the process progresses: move buyers between tiers based on engagement, add new names that emerge, remove buyers who have passed. Reassess after each process milestone.
</Accordion>

<Accordion title="Mistake 7: No Rationale Documented for Each Buyer">
  **What goes wrong:** The buyer list is a spreadsheet of names with no explanation of why each buyer is included. When the MD presents the list to the client, they cannot explain why Buyer X is Tier 1 vs. Tier 2. The client loses confidence in the process.

  **How to avoid it:** For every buyer on the list, document the specific strategic rationale: "PPG Industries -- Tier 1: Direct competitor in aerospace coatings. Would gain 18% market share. \$5B+ in cash. Completed 3 acquisitions in 2023. Clear strategic fit."
</Accordion>

<Accordion title="Mistake 8: Overlooking International Buyers">
  **What goes wrong:** The buyer list is US-focused because the target is a US company. But European and Asian strategic buyers may have strong interest (market entry into US) and the financial capacity to pay a premium for geographic expansion.

  **How to avoid it:** Include international strategic buyers, especially those with: (1) a stated strategy to expand into the target's geography, (2) adjacent products that could benefit from the target's distribution, or (3) a history of cross-border M\&A.
</Accordion>

<Accordion title="Mistake 9: Not Verifying Financial Capacity">
  **What goes wrong:** A $500M revenue company is on the Tier 1 list for a $200M acquisition. But the potential buyer has $50M of cash, $300M of existing debt at 4.5x leverage, and no acquisition financing capacity. They express interest, sign the NDA, consume management time, and then cannot submit a competitive bid.

  **How to avoid it:** For strategic buyers, check: cash on balance sheet, existing leverage, debt capacity (could they raise acquisition financing?), market cap (is the target too large relative to the acquirer?). For PE firms, check: remaining capital in the fund, typical check size, and whether co-investment or club deals are feasible.
</Accordion>

<Accordion title="Mistake 10: Contacting Tier 3 Too Early">
  **What goes wrong:** All 40 buyers are contacted simultaneously. The Tier 3 "longshot" buyers consume the same time and attention as Tier 1 strategic fits. The bank's bandwidth is spread thin, and Tier 1 buyers do not receive the personal attention they warrant.

  **How to avoid it:** Stagger outreach by tier. Contact Tier 1 first (personal calls from the MD). Wait 3-5 days, then contact Tier 2. Only contact Tier 3 if the response rate from Tiers 1-2 is below expectations. This preserves bandwidth for the highest-probability buyers.
</Accordion>

## Daily Workflow Scenarios

### Scenario 1: Building the Initial Buyer List (New Mandate)

**Day 1-2:** Research strategic buyers across all 4 categories. Use: company websites, industry reports, M\&A databases (PitchBook, Capital IQ), industry conference attendee lists.

**Day 3:** Research financial sponsors. Check: PitchBook for PE firms with sector-relevant portfolio companies, PE firm websites for stated sector theses, recent LP letters for investment themes.

**Day 4:** Tier the buyer list. Assign rationale for each. Prepare the contact mapping for Tier 1.

**Day 5:** Present to the deal team (VP/MD) for review. Then present to the client for approval and exclusions.

### Scenario 2: Updating the Buyer List After IOIs

**Context:** IOIs received. Two Tier 1 buyers submitted strong bids. One Tier 1 buyer passed. Three Tier 2 buyers submitted. Two Tier 2 buyers passed.

**Updates:**

* Move the Tier 1 buyer who passed to "Declined" status
* Reassess: Do we need to broaden to Tier 3?
* For finalists: verify updated financial capacity (can they fund the deal at the IOI price?)
* Add any new buyers identified during the process

## Practice Exercise

**Exercise: Build a Buyer Universe for a Healthcare IT Company**

You are advising on the sale of a healthcare IT company: $45M revenue, $9M EBITDA, 25% growth, cloud-based platform for hospital revenue cycle management.

**Task 1:** Identify 5 strategic buyers across the 4 categories (direct competitor, adjacent player, vertical integrator, platform builder). For each, provide: name, revenue, strategic fit rationale, and tier.

**Task 2:** Identify 3 financial sponsors. For each: name, fund size, sector relevance, and whether this would be a platform or add-on.

**Task 3:** For the top 2 Tier 1 buyers, create the contact mapping: key decision maker, relationship status, and recommended approach.

**Task 4:** Identify any potential antitrust concerns among your strategic buyers.

**Task 5:** How would your buyer list change if the company were growing at 5% instead of 25%? Which buyer categories become more or less relevant?

## How to Add to Your Local Context

```bash theme={null}
claude plugin install investment-banking@financial-services-plugins
```

```json theme={null}
{
  "mcpServers": {
    "pitchbook": {
      "command": "pitchbook-mcp-server",
      "args": ["--api-key", "YOUR_KEY"]
    }
  }
}
```

## Best Practices

* **Quality over quantity**: 30-40 well-researched buyers beats 200 names
* **Research recent M\&A activity**: Buyers who just completed a deal are either hungry for more or tapped out
* **Check antitrust concerns**: Flag direct competitors that might face regulatory challenges
* **Financial sponsors -- check fund vintage**: Nearing end of investment period means more motivated to deploy
* **Always ask the seller**: Include or exclude specific names per client preference
* **Update the list as the process progresses**: Move buyers between tiers based on engagement
* **Include rationale for every name**: Documentation supports credibility with the client

## Dependencies

**Required:**

* Web search or M\&A database for buyer identification

**Optional:**

* PitchBook/Capital IQ for PE fund data and M\&A history
* CRM for relationship tracking
* Teaser skill for coordinated distribution